Target discovery Leverage NonExomics’ AI-driven discovery of 250k+ potential protein targets from the dark genome to identify collaboration opportunities with diagnostic and therapeutic development partners seeking novel targets across diverse diseases.

Rare cancer focus Explore partnerships around miniPROs and custom mini-protein platforms aimed at difficult-to-target rare cancers, aligning with Ordaōs Bio collaborations to co-develop targeted therapeutics and diagnostic tools.

Diverse modality readiness Position offerings across multiple therapeutic modalities (small molecules, antisense oligos, antibodies, gene therapy) to meet customer needs and expand joint development programs leveraging NonExomics’ target portfolio.

Early-stage validation Highlight extensive in silico and experimental validation pipelines, underscoring readiness to de-risk early-stage collaborations and accelerate partner evaluation for target-to-diagnostic/therapeutic programs.

Growing yet lean Capitalize on the company’s nimble, scientist-led team with a recent platform launch and modest funding; propose co-development or sponsored research arrangements with larger biotech and pharma players seeking innovation at a favorable investment profile.